Chiron deal cleared
This article was originally published in The Gray Sheet
Executive Summary
European Commission approves Novartis' $5.1 bil. acquisition of blood-test and vaccine producer Chiron, passing the deal into the hands of shareholders. In the U.S., FTC cleared the deal at the end of 2005. Chiron anticipates that the acquisition will be completed before the end of the second quarter. Chiron and Novartis began moving toward a merger in September 2005 (1"The Gray Sheet" Nov. 7, 2005, In Brief)...
You may also be interested in...
Novartis buys Chiron
Novartis enters definitive agreement with Chiron Oct. 31 to buy the remaining 58% of the company for $45 a share, or about $5.1 bil. in cash. The deal is subject to approval of Chiron's shareholders, other than Novartis, and is expected to close in early 2006. In August, Chiron's board of directors rejected a buyout offer from Novartis of $40 per share ($4.5 bil.) (1"The Gray Sheet" Sept. 12, 2005, In Brief). On Nov. 3, Novartis announced its intention to appoint its current Global Head of Pharma Development Joerg Reinhardt, PhD, to head-up the new diagnostics and vaccines division that will be created from Chiron business units...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.